ClinicalTrials.gg

Program

VVN461

A development code. Also written as “VVN461 Ophthalmic Solution 1.0%”, “VVN461 Ophthalmic Solution 0.5%” and “VVN461 Ophthalmic Solution 0.25%”.

Its studies are mostly in Uveitis, Anterior · Inflammation, led by VivaVision Biotech.

Furthest: phase 3, since Aug 15, 20254 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
VivaVision Biotech41 open or runningphase 3since Aug 15, 2025Dec 1, 2023Dec 31, 2026phase 3 · NCT07136805

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2023First study: phase 2 study in InflammationFirst studyNCT06164743 · 91 enrolled · United States
  2. Nov 5, 2024Phase 2 study in Uveitis, AnteriorNCT06679153 · 89 enrolled · China
  3. Dec 3, 2024Phase 1 study in Healthy VolunteersNCT06906198 · 30 enrolled · China
  4. Aug 15, 2025Phase 3 study in Non-infectious Anterior UveitisNCT07136805 · 154 enrolled · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Non-infectious Anterior UveitisNCT07136805

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07136805Non-infectious Anterior Uveitis · China3Active, not recruitingDec 31, 2026154
NCT06906198Healthy Volunteers · China1CompletedMay 10, 202330
NCT06679153Uveitis, Anterior · China2CompletedDec 29, 202489
NCT06164743Inflammation · United States2CompletedMay 15, 202491

How it is read

Names in the registry

  • “VVN461 Ophthalmic Solution 1.0%”, 4 entries
  • “VVN461 Ophthalmic Solution 0.5%”, 3 entries
  • “VVN461 Ophthalmic Solution 0.25%”, 1 entry

Codes read as this program: VVN461.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.